IP Library Granted Patent US 7,494,774
Granted Patent B2
US 7,494,774 · App. 10/712,654 · Granted Feb 24, 2009

Assay and compositions for detection of

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,494,774
App. No.
10/712,654
Granted
Feb 24, 2009
Kind
B2
Abstract

The invention includes compositions and methods of detection of Bacillus anthracis that use oligonucleotide probes specific for genetic material contained in the pXO1 and pXO2 plasmids in nucleic acid hybridization reactions. Embodiments of the method may include additional probes specific for other gene sequences to distinguish B. anthracis from other bacterial species present in a sample or to provide an indication that the assay was performed properly even when no Bacillus sequence is detected.

Claims (16)

1. A composition comprising a synthetic oligonucleotide consisting of 25 to 40 nucleotides that hybridizes specifically to a B. anthracis pagA target sequence selected from the group consisting of SEQ ID Nos. 1, 2, 3, 4, 5, 6, 7, 8, 21, 22, 23, and 24, sequences fully complementary to SEQ ID Nos. 1, 2, 3, 4, 5, 6, 7, 8, 21, 22, 23, and 24, RNA equivalents of SEQ ID Nos. 1, 2, 3, 4, 5, 6, 7, 8, 21, 22, 23, and 24, and RNA sequences fully complementary to SEQ ID Nos. 1, 2, 3, 4, 5, 6, 7, 8, 21, 22, 23, and 24.

2. The composition of claim 1 , wherein the synthetic oligonucleotide that hybridizes specifically to the pagA target sequence consists of SEQ ID NO:1 or SEQ ID NO:2.

3. The composition of claim 1 , wherein the synthetic oligonucleotide that hybridizes specifically to the pagA target sequence consists of SEQ ID NO:3 or SEQ ID NO:4.

4. The composition of claim 1 , wherein the synthetic oligonucleotide that hybridizes specifically to the pagA target sequence consists of SEQ ID NO:5 or SEQ ID NO:6.

5. The composition of claim 1 , wherein the synthetic oligonucleotide that hybridizes specifically to the pagA target sequence consists of SEQ ID NO:7 or SEQ ID NO:8.

6. The composition of claim 1 further comprising a capB-specific synthetic oligonucleotide that hybridizes specifically to a capB target sequence, wherein the capB-specific oligonucleotide consists of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13 or SEQ ID NO:14.

7. The composition of claim 1 , wherein the synthetic oligonucleotide has a DNA or RNA backbone, or mixed DNA and RNA backbone, or contains at least one 2′-methoxy RNA group linking the bases.

8. The composition of claim 1 , wherein the synthetic oligonucleotide has a signal-producing label linked directly or indirectly to the oligonucleotide.

9. A kit comprising a synthetic oligonucleotide consisting of 25 to 40 nucleotides that hybridizes specifically to a sequence contained in a B. anthracis pagA target sequence selected from the group consisting of SEQ ID Nos. 1, 2, 3, 4, 5, 6, 7, 8, 21, 22, 23, and 24, sequences fully complementary to SEQ ID Nos. 1, 2, 3, 4, 5, 6, 7, 8, 21, 22, 23, and 24, RNA equivalents of SEQ ID Nos. 1, 2, 3, 4, 5, 6, 7, 8, 21, 22, 23, and 24, and RNA sequences fully complementary to SEQ ID Nos. 1, 2, 3, 4, 5, 6, 7, 8, 21, 22, 23, and 24.

10. The kit of claim 9 , further comprising a capB-specific probe oligonucleotide consisting of SEQ ID NO: 9, 10, 11, 12, 13 or 14.

11. A method of detecting B. anthracis nucleic acid in a sample comprising the steps of:

providing a sample containing B. anthracis nucleic acids;

providing a pagA-specific probe that hybridizes specifically to a pagA target sequence, wherein the pagA-specific probe is a synthetic oligonucleotide of 25 to 40 nucleotides selected from the group consisting of SEQ ID Nos. 1, 2, 3, 4, 5, 6, 7, 8, 21, 22, 23, and 24, sequences fully complementary to SEQ ID Nos. 1, 2, 3, 4, 5, 6, 7, 8, 21, 22, 23, and 24, RNA equivalents of SEQ ID Nos. 1, 2, 3, 4, 5, 6, 7, 8, 21, 22, 23, and 24, and RNA sequences fully complementary to SEQ ID Nos. 1, 2, 3, 4, 5, 6, 7, 8, 21, 22, 23, and 24;

hybridizing specifically at least one pagA-specific probe to the pagA target sequence; and

detecting the presence of at least one pagA-specific probe hybridized to the pagA target sequence to indicate the presence of B. anthracis in the sample.

12. The method of claim 11 further comprising a capB-specific probe oligonucleotide consisting of SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, or SEQ ID NO:14.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2003
From: NORMAN, SYLVIA A.; BUNGO, JENNIFER J.; HOGAN, JAMES J.; WEISBURG, WILLIAM G.
To: GEN-PROBE INCORPORATED
Reel/Frame 014706/0388 →